US judge ruling for FDA bars copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.
 · 9hFierce Pharma
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
Wegovy Gets Cheaper! Novo Nordisk Takes on Eli Lilly as Obesity Drug Battle Heats Up
Novo Nordisk A/S (NVO) has lowered prices of its blockbuster drug Wegovy for U.S. customers through a new direct-to-consumer online pharmacy,
Novo Nordisk launches NovoCare rivaling Eli Lilly’s LillyDirect
Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage
Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a federal judge denied a motion filed by a compounding trade group over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) weight loss drug Zepbound is no longer in shortage.

Eli Lilly, LifeMD and Teladoc

 · 5hModern Healthcare
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
Telehealth firms Teladoc, LifeMD tie up with Eli Lilly's pharmacy partner to offer Zepbound
LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound
LifeMD on Thursday said it will integrate with Eli Lilly's online pharmacy and healthcare platform to offer access to Lilly's prescription obesity treatment Zepbound in single-dose vials. LifeMD, a virtual primary care services provider,
The Washington Post13d
FDA says Ozempic shortage is over, chilling boom in off-brand versions
As drugmakers Novo Nordisk and Eli Lilly struggled to keep up with enormous demand for their diabetes and obesity drugs, the FDA designated their medicines in shortage in 2022 — and kept them there. That made it possible for pharmacies to craft their own ...
Fierce Pharma1d
Lilly’s 1st DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out about its atopic dermatitis treatment Ebglyss.
USA TODAY on MSN13d
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in December after the FDA found them to no longer be in short supply. The FDA said in a statement that compounding pharmacies ...
Court denying compounders’ motion positive for Eli Lilly, says Morgan Stanley
Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a
CNN on MSN13d
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Medical Marketing & Media2d
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
US judge bars copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.